Vis enkel innførsel

dc.contributor.authorNestvold, Janne M.
dc.contributor.authorWang, Mengyu
dc.contributor.authorCamilio, Ketil Andre
dc.contributor.authorZinöcker, Severin
dc.contributor.authorTjelle, Torunn Elisabeth
dc.contributor.authorLindberg, Alf
dc.contributor.authorHaug, Bengt Erik
dc.contributor.authorKvalheim, Gunnar
dc.contributor.authorSveinbjørnsson, Baldur
dc.contributor.authorRekdal, Øystein
dc.PublishedNestvold JM, Wang M, Camilio KA, Zinöcker SZ, Tjelle TE, Lindberg A, Haug BE, Kvalheim G, Sveinbjørnsson B, Rekdal Ø. Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. Oncoimmunology. 2017;6(8):e1338236eng
dc.description.abstractLTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as demonstrated by the regression of distal non-treated lesions. Significant infiltration of CD8+ T cells was observed in both treated and non-treated lesions, as shown by immunohistochemical and flow cytometric analysis. LTX-315 rapidly killed the cells in vitro with a lytic mode of action followed by the subsequent release of Danger-Associated Molecular Pattern (DAMP) molecules such as HMGB1, ATP and Cytochrome c. Together, our data demonstrate that LTX-315 represents a new approach to cancer immunotherapy, which has the potential as a novel immunotherapeutic agent.en_US
dc.publisherTaylor & Francisen_US
dc.rightsAttribution CC BY-NC-NDeng
dc.subjectoncolytic peptideeng
dc.titleOncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma modelen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2017 The Author(s)en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY-NC-ND
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY-NC-ND